In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study)

International Journal of Antimicrobial Agents

Volumn 53, Issue 2, 2019, Pages 177-184

  Kazmierczak, Krystyna M ^a   Tsuji, Masakatsu ^b   Wise, Mark G ^a   Hackel, Meredith ^a   Yamano, Yoshinori ^b   Echols, Roger ^c   Sahm, Daniel F ^a  

^a Division of Microbiology   (United States)

^b SHIONOGI AND CO LTD   (Japan)

^c Clinical Development and Medical Affairs LLC   (United States)

Author keywords

carbapenemase; cefiderocol; Gram negative bacteria; meropenem non susceptible

Indexed keywords

CARBAPENEM; CEFIDEROCOL; CEPHALOSPORIN; PORIN; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; CARBAPENEMASE; CEPHALOSPORIN DERIVATIVE;

ACINETOBACTER BAUMANNII; ALGORITHM; ANTIBACTERIAL ACTIVITY; ARTICLE; BACILLI; BACTERIUM ISOLATE; CORRELATIONAL STUDY; DRUG RESISTANCE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MIC90; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PSEUDOMONAS AERUGINOSA; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; DRUG EFFECT; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CEPHALOSPORINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA;

EID: 85058937250     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2018.10.007     Document Type: Article

References (20)

1. Bush, K., Jacoby, G.A., Updated functional classification of β-lactamases. Antimicrob Agents Chemother 54 (2010), 969–976.
2. Jacoby, G.A., Mills, D.M., Chow, N., Role of β-lactamases and porins in resistance to ertapenem and other β-lactams in Klebsiella pneumoniae. Antimicrob Agents Chemother 48 (2004), 3203–3206.
3. Babouee Flury, B., Ellington, M.J., Hopkins, K.L., Turton, J.F., Doumith, M., Loy, R., et al. Association of novel nonsynonymous single nucleotide polymorphisms in ampD with cephalosporin resistance and phylogenetic variations in ampC, ampR, ompF, and ompC in Enterobacter cloacae isolates that are highly resistant to carbapenems. Antimicrob Agents Chemother 60 (2016), 2383–2390.
4. Livermore, D.M., Interplay of impermeability and chromosomal β-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 36 (1992), 2046–2048.
5. Lister, P.D., Wolter, D.J., Hanson, N.D., Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 22 (2009), 582–610.
6. Li, X.-Z., Plesiat, P., Nikaido, H., The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clin Microbiol Rev 28 (2015), 337–418.
7. Bush, K., Carbapenemases: partners in crime. J Glob Antimicrob Resist 1 (2013), 7–16.
8. World Health Organization (WHO). Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis, 2017 (WHO/EMP/IAU/2017.12).
9. Brooke, J.S., Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev 25 (2012), 2–41.
10. Boucher, H.W., Talbot, G.H., Bradley, J.S., Edwards, J.E. Jr, Gilbert, D., Rice, L.B., et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48 (2009), 1–12.
11. Ito, A., Sato, T., Ota, M., Takemura, M., Nishikawa, T., Toba, S., et al. In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria. Antimicrob Agents Chemother, 62, 2018 e01454-17.
12. Hackel, M.A., Tsuji, M., Yamano, Y., Echols, R., Karlowsky, J.A., Sahm, D.F., In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant Gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 Study). Antimicrob Agents Chemother, 61, 2017 e00093-17.
13. Hackel, M.A., Tsuji, M., Yamano, Y., Echols, R., Karlowsky, J.A., Sahm, D.F., In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of Gram-negative bacilli collected worldwide in 2014 to 2016. Antimicrob Agents Chemother, 62, 2018 e01968-17.
14. Ito, A., Nishikawa, T., Matsumoto, S., Yoshizawa, H., Sato, T., Nakamura, R., et al. Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother 60 (2016), 7396–7401.
15. Kohira, N., West, J., Ito, A., Ito-Horiyama, T., Nakamura, R., Sato, T., et al. In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains. Antimicrob Agents Chemother 60 (2016), 729–734.
16. Ito-Horiyama, T., Ishii, Y., Ito, A., Sato, T., Nakamura, R., Fukuhara, N., et al. Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases. Antimicrob Agents Chemother 60 (2016), 4384–4386.
17. Ito, A., Kohira, N., Bouchillon, S.K., West, J., Rittenhouse, S., Sader, H.S., et al. In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. J Antimicrob Chemother 71 (2016), 670–677.
18. Dobias, J., Denervaud-Tendon, V., Poirel, L., Nordmann, P., Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens. Eur J Clin Microbiol Infect Dis 36 (2017), 2319–2327.
19. Clinical and Laboratory Standards Institute. June 2018 AST Meeting minutes and presentations, Breakpoint Working Group Report 2, https://clsi.org/media/2307/2018_june_ast_bpwg_report_2__dapto_ceftaroline_cefiderocol.pdf [Accessed 20 September 2018].
20. Falagas, M.E., Skalidis, T., Vardakas, K.Z., Legakis, N.J., the Hellenic Cefiderocol Study Group. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals. J Antimicrob Chemother 72 (2017), 1704–1708.